JP5735988B2 - ジヒドロピリドフタラジノン誘導体を合成する方法 - Google Patents
ジヒドロピリドフタラジノン誘導体を合成する方法 Download PDFInfo
- Publication number
- JP5735988B2 JP5735988B2 JP2012552143A JP2012552143A JP5735988B2 JP 5735988 B2 JP5735988 B2 JP 5735988B2 JP 2012552143 A JP2012552143 A JP 2012552143A JP 2012552143 A JP2012552143 A JP 2012552143A JP 5735988 B2 JP5735988 B2 JP 5735988B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- acid
- salt
- reducing reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*1C(CC(c(c2c3)c(*)cc3N)OC2=O)=*C=*1 Chemical compound C*1C(CC(c(c2c3)c(*)cc3N)OC2=O)=*C=*1 0.000 description 2
- IHYDPJKFRHSULT-WTKPLQERSA-N C[n]1ncnc1/C=C(/c(c1cc(F)c2)c2[N+]([O-])=O)\OC1=O Chemical compound C[n]1ncnc1/C=C(/c(c1cc(F)c2)c2[N+]([O-])=O)\OC1=O IHYDPJKFRHSULT-WTKPLQERSA-N 0.000 description 2
- RFNLRJMPADAXDJ-LSFURLLWSA-N C[n]1ncnc1CC(c(c1cc(F)c2)c2/N=C/c(cc2)ccc2F)=NNC1=O Chemical compound C[n]1ncnc1CC(c(c1cc(F)c2)c2/N=C/c(cc2)ccc2F)=NNC1=O RFNLRJMPADAXDJ-LSFURLLWSA-N 0.000 description 2
- XXDQPHJAXVFCLF-UHFFFAOYSA-N CC1(C=CC(C(C(c2ncn[n]2C)C2=NNC3=O)Nc4c2c3cc(F)c4)=CC1)F Chemical compound CC1(C=CC(C(C(c2ncn[n]2C)C2=NNC3=O)Nc4c2c3cc(F)c4)=CC1)F XXDQPHJAXVFCLF-UHFFFAOYSA-N 0.000 description 1
- DUGSNOOJQVCJDT-UHFFFAOYSA-N CCN(C(C)c(cc1)ccc1F)O Chemical compound CCN(C(C)c(cc1)ccc1F)O DUGSNOOJQVCJDT-UHFFFAOYSA-N 0.000 description 1
- STBHZIUGMZSHFC-UHFFFAOYSA-N CN/C(/CC(c(c(C(OC)=O)cc(F)c1)c1[N+]([O-])=O)=O)=N\C=N Chemical compound CN/C(/CC(c(c(C(OC)=O)cc(F)c1)c1[N+]([O-])=O)=O)=N\C=N STBHZIUGMZSHFC-UHFFFAOYSA-N 0.000 description 1
- CELADJBVKCWSPO-CHHVJCJISA-N C[n]1ncnc1/C(/C(c(c(C(OC)=O)cc(F)c1)c1[N+]([O-])=O)=O)=C\c(cc1)ccc1F Chemical compound C[n]1ncnc1/C(/C(c(c(C(OC)=O)cc(F)c1)c1[N+]([O-])=O)=O)=C\c(cc1)ccc1F CELADJBVKCWSPO-CHHVJCJISA-N 0.000 description 1
- HWGQMRYQVZSGDQ-UHFFFAOYSA-N C[n]1ncnc1C(C(c(cc1)ccc1F)Nc1c2c3cc(F)c1)C2=NNC3=O Chemical compound C[n]1ncnc1C(C(c(cc1)ccc1F)Nc1c2c3cc(F)c1)C2=NNC3=O HWGQMRYQVZSGDQ-UHFFFAOYSA-N 0.000 description 1
- PAJDMXUECFRDFU-UHFFFAOYSA-N C[n]1ncnc1CC(c(c1cc(F)c2)c2N)=NNC1=O Chemical compound C[n]1ncnc1CC(c(c1cc(F)c2)c2N)=NNC1=O PAJDMXUECFRDFU-UHFFFAOYSA-N 0.000 description 1
- PVAIIDFKUPYMQA-IRXDYDNUSA-N C[n]1ncnc1[C@@H]([C@H](c(cc1)ccc1F)Nc1cc(F)cc(C(OC)=O)c11)C1=O Chemical compound C[n]1ncnc1[C@@H]([C@H](c(cc1)ccc1F)Nc1cc(F)cc(C(OC)=O)c11)C1=O PVAIIDFKUPYMQA-IRXDYDNUSA-N 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N O=Cc(cc1)ccc1F Chemical compound O=Cc(cc1)ccc1F UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30245710P | 2010-02-08 | 2010-02-08 | |
| US61/302,457 | 2010-02-08 | ||
| PCT/US2011/023965 WO2011097602A1 (en) | 2010-02-08 | 2011-02-08 | Processes of synthesizing dihydropyridophthalazinone derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518910A JP2013518910A (ja) | 2013-05-23 |
| JP2013518910A5 JP2013518910A5 (https=) | 2014-03-27 |
| JP5735988B2 true JP5735988B2 (ja) | 2015-06-17 |
Family
ID=44354222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012552143A Active JP5735988B2 (ja) | 2010-02-08 | 2011-02-08 | ジヒドロピリドフタラジノン誘導体を合成する方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8765945B2 (https=) |
| EP (1) | EP2533640B1 (https=) |
| JP (1) | JP5735988B2 (https=) |
| KR (1) | KR101826652B1 (https=) |
| CN (1) | CN102834008B (https=) |
| AU (1) | AU2011213584B2 (https=) |
| BR (1) | BR112012019648B1 (https=) |
| CA (1) | CA2788114C (https=) |
| CY (1) | CY1118575T1 (https=) |
| DK (1) | DK2533640T3 (https=) |
| ES (1) | ES2606174T3 (https=) |
| HU (1) | HUE030794T2 (https=) |
| IL (1) | IL221170A (https=) |
| MX (1) | MX340319B (https=) |
| PL (1) | PL2533640T3 (https=) |
| PT (1) | PT2533640T (https=) |
| RU (1) | RU2561732C2 (https=) |
| SG (1) | SG182784A1 (https=) |
| SI (1) | SI2533640T1 (https=) |
| WO (1) | WO2011097602A1 (https=) |
| ZA (1) | ZA201205538B (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2625817T3 (es) | 2008-08-06 | 2017-07-20 | Medivation Technologies, Inc. | Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP) |
| CA2787844C (en) | 2010-02-03 | 2019-08-27 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency |
| PT2533640T (pt) | 2010-02-08 | 2017-01-03 | Medivation Technologies Inc | Processos de síntese de derivados de di-hidropiridoftalazinona |
| NZ609490A (en) | 2010-10-21 | 2015-06-26 | Biomarin Pharm Inc | Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt |
| EP3038600B1 (en) | 2013-08-27 | 2020-06-03 | Northeastern University | Nanoparticle drug delivery system and method of treating cancer and neurotrauma |
| TW201605814A (zh) | 2013-11-07 | 2016-02-16 | 拜奧馬林製藥公司 | 用於合成經保護之ｎ－烷基三唑甲醛的三唑中間體 |
| SG11201700734RA (en) * | 2014-07-31 | 2017-02-27 | Medivation Technologies Inc | Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them |
| CN104557917A (zh) * | 2014-12-12 | 2015-04-29 | 重庆博腾制药科技股份有限公司 | 一种5-卤代氮杂环吲哚的制备方法 |
| JP6786761B2 (ja) * | 2015-05-26 | 2020-11-18 | ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． | Ｓｆｃによるキラル異性体の分離 |
| US9708319B1 (en) * | 2016-06-13 | 2017-07-18 | Yong Xu | Synthesis of PARP inhibitor talazoparib |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| KR20200071097A (ko) | 2017-10-13 | 2020-06-18 | 메르크 파텐트 게엠베하 | Parp 억제제 및 pd-1 축 결합 길항제의 조합 |
| TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
| EP3876940A1 (en) | 2018-11-05 | 2021-09-15 | Pfizer Inc. | Combinations for treating cancer |
| CA3174908A1 (en) | 2020-03-09 | 2021-09-16 | Pfizer Inc. | Fusion proteins and uses thereof |
| CA3201467A1 (en) | 2020-11-13 | 2022-05-19 | Pfizer Inc. | Talazoparib soft gelatin capsule dosage form |
| JP2023551968A (ja) | 2020-12-07 | 2023-12-13 | ファイザー・インク | タラゾパリブでの処置に対して感受性のある腫瘍を同定する方法およびその処置方法 |
| BR112023018906A2 (pt) | 2021-03-24 | 2023-10-10 | Astellas Pharma Inc | Combinação de talazoparib e um antiandrógeno para o tratamento de câncer de próstata metastático sensível à castração com mutação no gene ddr |
| WO2023131894A1 (en) | 2022-01-08 | 2023-07-13 | Pfizer Inc. | Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof |
| TWI883565B (zh) | 2022-10-02 | 2025-05-11 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202425976A (zh) | 2022-12-17 | 2024-07-01 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202600137A (zh) | 2024-04-04 | 2026-01-01 | 美商輝瑞股份有限公司 | 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法 |
| WO2026078619A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
| WO2026078615A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4415504A (en) | 1981-09-21 | 1983-11-15 | Tanabe Seiyaku Co., Ltd. | p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine |
| JPS58225065A (ja) | 1982-06-21 | 1983-12-27 | Nippon Shinyaku Co Ltd | ２−キノロン誘導体 |
| US5328905A (en) | 1987-07-20 | 1994-07-12 | Duphar International Research B.V. | 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives |
| SK278998B6 (sk) * | 1991-02-01 | 1998-05-06 | Merck Sharp & Dohme Limited | Deriváty imidazolu, triazolu a tetrazolu, spôsob i |
| GB9505538D0 (en) | 1995-03-18 | 1995-05-03 | Ciba Geigy Ag | New compounds |
| ID19155A (id) | 1996-12-13 | 1998-06-18 | Tanabe Seiyaku Co | Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya |
| DE19727410A1 (de) | 1997-06-27 | 1999-01-07 | Hoechst Schering Agrevo Gmbh | 3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| TW430656B (en) | 1997-12-03 | 2001-04-21 | Dainippon Ink & Chemicals | Quinolinone derivative, method for preparing the same, and anti-allergic agent |
| CA2332239A1 (en) | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
| DE19921567A1 (de) | 1999-05-11 | 2000-11-16 | Basf Ag | Verwendung von Phthalazine-Derivaten |
| JP2001302669A (ja) * | 2000-04-18 | 2001-10-31 | Meiji Seika Kaisha Ltd | 三環性フタラジノン誘導体 |
| JP2002284699A (ja) | 2001-03-28 | 2002-10-03 | Sumitomo Pharmaceut Co Ltd | 視細胞変性疾患治療剤 |
| AR036081A1 (es) | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos |
| SE0102315D0 (sv) | 2001-06-28 | 2001-06-28 | Astrazeneca Ab | Compounds |
| RU2292337C2 (ru) * | 2002-02-19 | 2007-01-27 | Оно Фармасьютикал Ко., Лтд. | Конденсированные производные пиридазина и лекарственные препараты, содержащие данные соединения в качестве активного ингредиента |
| EP1340819A1 (en) | 2002-02-28 | 2003-09-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Microsatellite markers |
| GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
| EP1400244A1 (en) | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
| JPWO2004043959A1 (ja) | 2002-11-12 | 2006-03-09 | 持田製薬株式会社 | 新規ｐａｒｐ阻害剤 |
| BRPI0408284B8 (pt) * | 2003-03-12 | 2021-05-25 | Kudos Pharm Ltd | compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos |
| WO2004105700A2 (en) | 2003-05-28 | 2004-12-09 | Guildford Pharmaceuticals, Inc. | Compounds, methods and pharmaceutical compositions for inhibiting parp |
| US7269138B2 (en) * | 2003-06-04 | 2007-09-11 | Motorola, Inc. | Distributed MAC protocol facilitating collaborative ranging in communications networks |
| TW200533664A (en) | 2004-02-18 | 2005-10-16 | Astrazeneca Ab | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists |
| GB0612971D0 (en) | 2006-06-30 | 2006-08-09 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| GEP20125379B (en) | 2007-05-03 | 2012-01-10 | Pfizer Ltd | 2 -pyridine carboxamide derivatives as sodium channel modulators |
| JP2010536807A (ja) | 2007-08-22 | 2010-12-02 | ４エスツェー アクチェンゲゼルシャフト | キネシンスピンドルタンパク質（ｅｇ５）の阻害剤としてのインドロピリジン |
| DK2209375T3 (da) * | 2007-10-03 | 2014-10-06 | Eisai Inc | Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf |
| WO2009099736A2 (en) | 2008-02-06 | 2009-08-13 | Lead Therapeutics, Inc. | Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp) |
| ES2625817T3 (es) | 2008-08-06 | 2017-07-20 | Medivation Technologies, Inc. | Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP) |
| US20110301350A1 (en) | 2008-08-12 | 2011-12-08 | Boehringer Ingelheim International Gmbh | Process for preparing cycloalkyl-substituted piperazine compounds |
| CA2787844C (en) | 2010-02-03 | 2019-08-27 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency |
| US20110190266A1 (en) | 2010-02-04 | 2011-08-04 | Daniel Chu | 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) |
| PT2533640T (pt) | 2010-02-08 | 2017-01-03 | Medivation Technologies Inc | Processos de síntese de derivados de di-hidropiridoftalazinona |
| WO2011130661A1 (en) | 2010-04-16 | 2011-10-20 | Biomarin Pharmaceutical Inc. | Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp) |
| WO2011140009A1 (en) | 2010-05-04 | 2011-11-10 | Biomarin Pharmaceutical Inc. | Methods of using semi-synthetic glycopeptides as antibacterial agents |
| NZ609490A (en) | 2010-10-21 | 2015-06-26 | Biomarin Pharm Inc | Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt |
| WO2012166151A1 (en) | 2011-06-03 | 2012-12-06 | Biomarin Pharmaceutical Inc. | Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml) |
| WO2013028495A1 (en) | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma |
| US20130053365A1 (en) | 2011-08-30 | 2013-02-28 | Biomarin Pharmaceutical, Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| TW201605814A (zh) | 2013-11-07 | 2016-02-16 | 拜奧馬林製藥公司 | 用於合成經保護之ｎ－烷基三唑甲醛的三唑中間體 |
| SG11201700734RA (en) | 2014-07-31 | 2017-02-27 | Medivation Technologies Inc | Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them |
-
2011
- 2011-02-08 PT PT117405134T patent/PT2533640T/pt unknown
- 2011-02-08 BR BR112012019648-0A patent/BR112012019648B1/pt not_active IP Right Cessation
- 2011-02-08 PL PL11740513T patent/PL2533640T3/pl unknown
- 2011-02-08 EP EP11740513.4A patent/EP2533640B1/en active Active
- 2011-02-08 WO PCT/US2011/023965 patent/WO2011097602A1/en not_active Ceased
- 2011-02-08 SG SG2012056123A patent/SG182784A1/en unknown
- 2011-02-08 HU HUE11740513A patent/HUE030794T2/en unknown
- 2011-02-08 CN CN201180017690.6A patent/CN102834008B/zh active Active
- 2011-02-08 ES ES11740513.4T patent/ES2606174T3/es active Active
- 2011-02-08 SI SI201131061T patent/SI2533640T1/sl unknown
- 2011-02-08 US US13/023,140 patent/US8765945B2/en active Active
- 2011-02-08 CA CA2788114A patent/CA2788114C/en active Active
- 2011-02-08 JP JP2012552143A patent/JP5735988B2/ja active Active
- 2011-02-08 RU RU2012138345/04A patent/RU2561732C2/ru active
- 2011-02-08 KR KR1020127021601A patent/KR101826652B1/ko not_active Expired - Fee Related
- 2011-02-08 AU AU2011213584A patent/AU2011213584B2/en not_active Ceased
- 2011-02-08 MX MX2012008903A patent/MX340319B/es active IP Right Grant
- 2011-02-08 DK DK11740513.4T patent/DK2533640T3/en active
-
2012
- 2012-07-23 ZA ZA2012/05538A patent/ZA201205538B/en unknown
- 2012-07-29 IL IL221170A patent/IL221170A/en active IP Right Grant
-
2014
- 2014-06-02 US US14/293,642 patent/US9926303B2/en active Active
-
2016
- 2016-12-28 CY CY20161101354T patent/CY1118575T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5735988B2 (ja) | ジヒドロピリドフタラジノン誘導体を合成する方法 | |
| KR102040382B1 (ko) | Ask1 억제제의 제조 방법 | |
| CN107849049B (zh) | 脲衍生物或其药用盐 | |
| KR20200131241A (ko) | 2종의 4-｛[(2s)-2-｛4-[5-클로로-2-(1h-1,2,3-트리아졸-1-일)페닐]-5-메톡시-2-옥소피리딘-1(2h)-일}부타노일]아미노}-2-플루오로벤즈아미드 유도체의 제조 방법 | |
| EP2225202B1 (en) | Preparation of dihydropyrrol derivatives as intermediates | |
| JP6275881B2 (ja) | デュオカルマイシンのプロドラッグを製造するための改良された方法 | |
| US12077528B2 (en) | Preparation method for deuterated macrocyclic compound | |
| JP2018516912A (ja) | アプレミラストおよびその新規な多形の改善された製造方法 | |
| CN116367832B (zh) | 取代的杂芳基化合物及其用途 | |
| HK1179945B (en) | Processes of synthesizing dihydropyridophthalazinone derivatives | |
| CN115850240A (zh) | 一种治疗急性髓系白血病药物奥卢他西尼的合成方法 | |
| KR101426533B1 (ko) | 도파민 ｄ4 수용체 선택적 활성 리간드로 작용하는 1-페닐-4-(1,2,3-트리아졸-1-일알킬)피페라진 화합물 | |
| WO2007037303A1 (ja) | テトラ置換－５－アザスピロ[２．４]へプタン誘導体の製法およびその光学活性中間体 | |
| HK40035144B (zh) | 两种化合物的制备方法 | |
| KR20110048337A (ko) | 히스톤 디아세틸라제 저해활성을 갖는 6-아미노-ν-하이드록시헥산아마이드 화합물 및 이의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140206 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140206 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141202 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20141204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150227 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150407 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150417 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5735988 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |